Nature's latest research paper: Two new crown vaccines for clinical trials.

A single-dose vaccine made from adenovirus and a ChAdOx1 nCoV-19 vaccine for the new coronavirus (SARS-CoV-2) are in clinical trials, both of which have been shown to protect non-human primates from new coronaviruses and prevent the occurrence of new co-op strains, according to two papers published online by nature, the international leading academic journal Nature.
safe and effective new coronavirus vaccine has become a global priority. A single-dose vaccine made from adenovirus escants could protect rhesus monkeys from the new coronavirus, and the best version of the vaccine is currently being evaluated in clinical trials, according to a paper published in
Nature.
vector-based vaccine uses fragments of the virus to express the target pathogen to stimulate the immune response, adenovirus is a group of viruses associated with diseases such as mild cold, can effectively invade human cells.
a vaccine based on adenovirus serotype 26 (Ad26) has been shown to induce an immune response to various pathogens in non-human primates and humans.
the paper's author, Dan Barouch of Harvard Medical School in the United States, and colleagues developed a series of Ad26 vectors that encode different variants of the new coronavirus sting protein and showed test results in 52 adult rhesus monkeys.
their research that these vaccines can cause an immune response and provide some or all of the protection against infection in the respiratory tract of the new coronavirus, an effect that is considered necessary to prevent the spread and onset of the virus in humans, with the best performing vaccine, Ad26-S.PP (vaccine name Ad26.COV2.S), now in clinical trials.
authors say that a single dose of vaccine can provide a strong response, single dose of the new coronavirus vaccine than multi-dose vaccine has a practical advantage.
, however, they hope that the two-dose injection of the Ad26-S.PP vaccine will produce a stronger immune response. Another paper published
Nature suggests that the ChAdOx1 nCoV-19 vaccine for the new coronavirus is currently undergoing human clinical trials in the UK that can trigger an immune response and reduce viral load strain on rhesus monkeys exposed to the new coronavirus.
the vaccine was found to prevent rhesus monkeys from developing new coronapneumonia, the preliminary results of its research were used to facilitate the launch of clinical trials of the vaccine in humans.
the paper's author, Vincent Munster of the National Institute of Allergy and Infectious Diseases, said ChAdOx1 nCoV-19 was made of weakened chimpanzee adenovirus, a group of viruses that cause a range of diseases, including the common cold, that express the new coronavirus stingprotein, a structure that allows the new coronavirus to enter human cells.
Vincent Munster and colleagues have shown that giving six rhesus monkeys a dose of ChAdOx1 nCoV-19 28 days before exposure to the new coronavirus can prevent lung damage and significantly reduce viral load (compared to six control animals).
six other rhesus monkeys were given two doses of the vaccine in the 56 and 28 days before the challenge, showing an increased immune response.
the authors note that there is no difference between a virus that falls out of the nose in a vaccinated animal and a control animal, a finding that ChAdOx1 nCoV-19 may not prevent infection or transmission, but may reduce the disease.
the study has led to clinical trials of the ChAdOx1 nCov-19 vaccine, with more than 8,000 volunteers involved as of early July 2020.
(Complete)